Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): Results of a provincial strategy

A. D. Schimmer, S. Jamal, H. Messner, A. Keating, J. Meharchand, L. Huebsch, I. Walker, A. Benger, S. Gluck, A. Smith

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

In 1986, the bone marrow transplant centers in Ontario agreed to a strategy for the treatment of patients with NHL. Suitable patients would undergo autotransplant but be referred for allotransplant if they had persistent marrow involvement or an inadequate marrow/stem cell harvest. Data of all patients were recorded in a database. We reviewed this database to compare these transplant modalities with respect to overall survival, rate of relapse and treatment-related mortality. Between January 1986 and August 1997, 429 patients underwent BMT for NHL - 385 autotransplants and 44 allotransplants. Sixty-eight percent of patients received their transplant for aggressive NHL, while the others had indolent lymphoma. Three-year actuarial survival did not differ between allogeneic and autologous BMT: 71% vs 62%, respectively (P = 0.5330 by log-rank testing). Three-year actuarial rate of relapse was lower after allotransplant than autotransplant: 6% vs 41%, respectively (P = 0.0006 by log-rank testing). Treatment-related mortality was higher after allotransplant than autotransplant: 23% vs 6%, respectively (P = 0.001 by χ2 analysis). For further comparison, autotransplant patients were randomly matched 2:1 with the allotransplant patients for age ± 5 years, disease status at BMT, disease histology, and years of BMT. In the matched comparison, survival did not differ (relative risk of death after allotransplant: 0.711 (95% CI: 0.309-1.637)). Relapse rate was significantly lower in the allotransplant group (relative risk of relapse for allotransplant: 0.190 (95% CI: 0.043-0.834)) and treatment-related mortality was not significantly different (relative risk for allotransplant: 1.425 (95% CI: 0.527-3.851)). In conclusion, a review of a provincial strategy for treatment of NHL, shows that survival is not different after allogeneic or autologous BMT, but the rate of relapse is lower after allotransplant. These data support continuing the current provincial strategy.

Original languageEnglish
Pages (from-to)859-864
Number of pages6
JournalBone Marrow Transplantation
Volume26
Issue number8
StatePublished - Nov 18 2000
Externally publishedYes

Fingerprint

Autologous Transplantation
Bone Marrow Transplantation
Non-Hodgkin's Lymphoma
Autografts
Recurrence
Bone Marrow
Transplants
Survival
Mortality
Bone Marrow Diseases
Databases
Therapeutics
Ontario
Lymphoma
Histology
Stem Cells
Survival Rate

Keywords

  • Allotransplant
  • Autotransplant
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Schimmer, A. D., Jamal, S., Messner, H., Keating, A., Meharchand, J., Huebsch, L., ... Smith, A. (2000). Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): Results of a provincial strategy. Bone Marrow Transplantation, 26(8), 859-864.

Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL) : Results of a provincial strategy. / Schimmer, A. D.; Jamal, S.; Messner, H.; Keating, A.; Meharchand, J.; Huebsch, L.; Walker, I.; Benger, A.; Gluck, S.; Smith, A.

In: Bone Marrow Transplantation, Vol. 26, No. 8, 18.11.2000, p. 859-864.

Research output: Contribution to journalArticle

Schimmer, AD, Jamal, S, Messner, H, Keating, A, Meharchand, J, Huebsch, L, Walker, I, Benger, A, Gluck, S & Smith, A 2000, 'Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): Results of a provincial strategy', Bone Marrow Transplantation, vol. 26, no. 8, pp. 859-864.
Schimmer AD, Jamal S, Messner H, Keating A, Meharchand J, Huebsch L et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): Results of a provincial strategy. Bone Marrow Transplantation. 2000 Nov 18;26(8):859-864.
Schimmer, A. D. ; Jamal, S. ; Messner, H. ; Keating, A. ; Meharchand, J. ; Huebsch, L. ; Walker, I. ; Benger, A. ; Gluck, S. ; Smith, A. / Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL) : Results of a provincial strategy. In: Bone Marrow Transplantation. 2000 ; Vol. 26, No. 8. pp. 859-864.
@article{55549ed51c0c4e7b8b5e56b0de824c50,
title = "Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): Results of a provincial strategy",
abstract = "In 1986, the bone marrow transplant centers in Ontario agreed to a strategy for the treatment of patients with NHL. Suitable patients would undergo autotransplant but be referred for allotransplant if they had persistent marrow involvement or an inadequate marrow/stem cell harvest. Data of all patients were recorded in a database. We reviewed this database to compare these transplant modalities with respect to overall survival, rate of relapse and treatment-related mortality. Between January 1986 and August 1997, 429 patients underwent BMT for NHL - 385 autotransplants and 44 allotransplants. Sixty-eight percent of patients received their transplant for aggressive NHL, while the others had indolent lymphoma. Three-year actuarial survival did not differ between allogeneic and autologous BMT: 71{\%} vs 62{\%}, respectively (P = 0.5330 by log-rank testing). Three-year actuarial rate of relapse was lower after allotransplant than autotransplant: 6{\%} vs 41{\%}, respectively (P = 0.0006 by log-rank testing). Treatment-related mortality was higher after allotransplant than autotransplant: 23{\%} vs 6{\%}, respectively (P = 0.001 by χ2 analysis). For further comparison, autotransplant patients were randomly matched 2:1 with the allotransplant patients for age ± 5 years, disease status at BMT, disease histology, and years of BMT. In the matched comparison, survival did not differ (relative risk of death after allotransplant: 0.711 (95{\%} CI: 0.309-1.637)). Relapse rate was significantly lower in the allotransplant group (relative risk of relapse for allotransplant: 0.190 (95{\%} CI: 0.043-0.834)) and treatment-related mortality was not significantly different (relative risk for allotransplant: 1.425 (95{\%} CI: 0.527-3.851)). In conclusion, a review of a provincial strategy for treatment of NHL, shows that survival is not different after allogeneic or autologous BMT, but the rate of relapse is lower after allotransplant. These data support continuing the current provincial strategy.",
keywords = "Allotransplant, Autotransplant, Non-Hodgkin's lymphoma",
author = "Schimmer, {A. D.} and S. Jamal and H. Messner and A. Keating and J. Meharchand and L. Huebsch and I. Walker and A. Benger and S. Gluck and A. Smith",
year = "2000",
month = "11",
day = "18",
language = "English",
volume = "26",
pages = "859--864",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL)

T2 - Results of a provincial strategy

AU - Schimmer, A. D.

AU - Jamal, S.

AU - Messner, H.

AU - Keating, A.

AU - Meharchand, J.

AU - Huebsch, L.

AU - Walker, I.

AU - Benger, A.

AU - Gluck, S.

AU - Smith, A.

PY - 2000/11/18

Y1 - 2000/11/18

N2 - In 1986, the bone marrow transplant centers in Ontario agreed to a strategy for the treatment of patients with NHL. Suitable patients would undergo autotransplant but be referred for allotransplant if they had persistent marrow involvement or an inadequate marrow/stem cell harvest. Data of all patients were recorded in a database. We reviewed this database to compare these transplant modalities with respect to overall survival, rate of relapse and treatment-related mortality. Between January 1986 and August 1997, 429 patients underwent BMT for NHL - 385 autotransplants and 44 allotransplants. Sixty-eight percent of patients received their transplant for aggressive NHL, while the others had indolent lymphoma. Three-year actuarial survival did not differ between allogeneic and autologous BMT: 71% vs 62%, respectively (P = 0.5330 by log-rank testing). Three-year actuarial rate of relapse was lower after allotransplant than autotransplant: 6% vs 41%, respectively (P = 0.0006 by log-rank testing). Treatment-related mortality was higher after allotransplant than autotransplant: 23% vs 6%, respectively (P = 0.001 by χ2 analysis). For further comparison, autotransplant patients were randomly matched 2:1 with the allotransplant patients for age ± 5 years, disease status at BMT, disease histology, and years of BMT. In the matched comparison, survival did not differ (relative risk of death after allotransplant: 0.711 (95% CI: 0.309-1.637)). Relapse rate was significantly lower in the allotransplant group (relative risk of relapse for allotransplant: 0.190 (95% CI: 0.043-0.834)) and treatment-related mortality was not significantly different (relative risk for allotransplant: 1.425 (95% CI: 0.527-3.851)). In conclusion, a review of a provincial strategy for treatment of NHL, shows that survival is not different after allogeneic or autologous BMT, but the rate of relapse is lower after allotransplant. These data support continuing the current provincial strategy.

AB - In 1986, the bone marrow transplant centers in Ontario agreed to a strategy for the treatment of patients with NHL. Suitable patients would undergo autotransplant but be referred for allotransplant if they had persistent marrow involvement or an inadequate marrow/stem cell harvest. Data of all patients were recorded in a database. We reviewed this database to compare these transplant modalities with respect to overall survival, rate of relapse and treatment-related mortality. Between January 1986 and August 1997, 429 patients underwent BMT for NHL - 385 autotransplants and 44 allotransplants. Sixty-eight percent of patients received their transplant for aggressive NHL, while the others had indolent lymphoma. Three-year actuarial survival did not differ between allogeneic and autologous BMT: 71% vs 62%, respectively (P = 0.5330 by log-rank testing). Three-year actuarial rate of relapse was lower after allotransplant than autotransplant: 6% vs 41%, respectively (P = 0.0006 by log-rank testing). Treatment-related mortality was higher after allotransplant than autotransplant: 23% vs 6%, respectively (P = 0.001 by χ2 analysis). For further comparison, autotransplant patients were randomly matched 2:1 with the allotransplant patients for age ± 5 years, disease status at BMT, disease histology, and years of BMT. In the matched comparison, survival did not differ (relative risk of death after allotransplant: 0.711 (95% CI: 0.309-1.637)). Relapse rate was significantly lower in the allotransplant group (relative risk of relapse for allotransplant: 0.190 (95% CI: 0.043-0.834)) and treatment-related mortality was not significantly different (relative risk for allotransplant: 1.425 (95% CI: 0.527-3.851)). In conclusion, a review of a provincial strategy for treatment of NHL, shows that survival is not different after allogeneic or autologous BMT, but the rate of relapse is lower after allotransplant. These data support continuing the current provincial strategy.

KW - Allotransplant

KW - Autotransplant

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0033752610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033752610&partnerID=8YFLogxK

M3 - Article

C2 - 11081385

AN - SCOPUS:0033752610

VL - 26

SP - 859

EP - 864

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -